The cost of HIV treatment and care: A global review

PharmacoEconomics

Volumn 19, Issue 1, 2001, Pages 13-39

  Beck, E J ^a,b   Miners, A H ^b,c   Tolley, K ^d  

^a MCGILL UNIVERSITY   (Canada)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CHILD; COST OF ILLNESS; HEALTH CARE COST; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

EID: 0035150913     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119010-00002     Document Type: Review

References (120)

1. Studying the cost of HIV-related illnesses: Reflections on the moving target
2. Variations in the care of HIV-infected adults in the United States: Results from the HIV cost and services utilization study
3. Pneumocystis pneumonia
4. Kaposi's sarcoma
5. AIDS epidemic update
6. HIV infection: The global perspective
7. AIDS: A global perspective
8. The interaction of HIV infection and other sexually transmitted diseases: An opportunity for intervention
9. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
10. Rapid turnover of plasma virions and CD4 lymphocytes on HIV-1 infection
11. Viral dynamics in human immunodeficiency virus type 1 infection
12. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
13. Advances in antiretroviral therapy and viral load monitoring
14. Delta: A randomised double blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals
15. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS
16. Decay characteristics of HIV-1-infected compartments during combination therapy
17. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
18. Reduced HIV disease progression and mortality due to combination antiretroviral therapy in English NPMS-HHC clinics [poster TuPeC3331 ]
19. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA Panel
20. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA Panel
21. Funding implications of combination therapies
22. River Path Association Something to be done treating HIV/AIDS
23. The distinction between costs and charges
24. What is the cost of getting the price wrong?
25. The treatment and care costs of people with HIV infection or AIDS: Development of a standardised cost framework for Europe
26. Background theory
27. The cost of acquired immunodeficiency syndrome in northern California. The experience of a large prepaid health plan
28. Analysis of Michigan Medicaid costs to treat HIV infection
29. Lifetime medical service utilization and expenditures for AIDS in New York and California
30. Medical care utilization and associated charges for patients with symptomatic HIV disease
31. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989
32. The costs of hospital-based medical care for patients with the acquired immunodeficiency syndrome
33. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months
34. Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS)
35. The costs of AIDS in Los Angeles
36. Comparisons of hospital care for patients with AIDS and other HIV-related conditions
37. Medical care costs of intravenous drug users with AIDS in Brooklyn
38. Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system
39. AIDS treatment costs during the last months of life: Evidence from the ACSUS
40. Costs of medical care and out-of-pocket expenditures for persons with AIDS in the Boston Health Study
41. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland
42. Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy
43. Medical care costs of patients with AIDS in Hawaii
44. Changing presentation and survival, service utilization and costs for AIDS patients: Insights from a London referral centre
45. Hospital costs of treating haemophilic patients infected with HIV
46. Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department
47. Survival and the use and costs of hospital services for London AIDS patients treated with AZT
48. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection
49. The cost of health care for HIV-positive patients
50. The use and cost of hospital services by London AIDS patients with different AIDS defining conditions
51. Hospital cost for patients with HIV infection in a University Hospital in the Netherlands
52. The usage and costs of health services for HIV infection in Australia
53. Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994
54. Hospital outpatient costs for patients with HIV infection
55. In-patient care for symptomatic, HIV-infected persons: A longitudinal study of hospitalizations, in-patient drug use, and related costs
56. Patient classification and cost analysis of AIDS and HIV: The case of Belgium
57. Financing HIV service provision in England: Estimated impact of the cost of antiretroviral combination therapy
58. The use and cost of HIV service provision in England in 1996
59. Changing cost of English HIV service provision, 1996-1997
60. Resource utilization patterns in patients with acquired immunodeficiency syndrome (AIDS)
61. Cost analysis of AIDS cases in Maryland
62. Medical care costs of patients with AIDS in San Francisco
63. Medical care costs of patients with acquired immunodeficiency syndrome in Richmond, Va. A quantitative analysis
64. Duration and costs of AIDS hospitalizations in New York. Variations by patient severity of illness and hospital type
65. Medical care costs of AIDS in Massachusetts
66. The acquired immune deficiency syndrome and epidemic of infection with human immunodeficiency virus: Costs of care and prevention in an inner London district
67. The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population
68. Financial aspects of the provision of care to AIDS patients at Hartford Hospital
69. Medication costs associated with the care of HIV-infected patients
70. The pattern and cost of hospital care for persons with HIV/AIDS in Guilford County, NC, 1987-1991
71. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990
72. U.S. hospital care for HIV-infected persons and the role of public and private teaching hospitals
73. Longitudinal patterns of medical service use and costs among people with AIDS
74. Medical care cost of ambulatory patients infected with the human immunodeficiency virus: Analysis at a Swiss outpatient clinic
75. CD4 lymphocyte count as a predictor of drug expenditure in a cohort of anti-HIV seropositive haemophiliacs
76. Hospital associated costs of treating patients with AIDS
77. The patient profile approach to assessing the cost of AIDS and HIV infection
78. The cost of adult AIDS inpatient care
79. Lifetime cost of treating a person with HIV infection
80. Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women
81. Costs of HIV medical care in the era of highly active antiretroviral therapy
82. Labor and cost in AIDS family caregiving
83. Williams T The private costs of HIV/AIDS
84. Cost and utilisation of community services for people with HIV infection in London
85. The economic costs of caring for people with HIV infection and AIDS in England and Wales
86. The cost of home-based care for HIV/AIDS patients in Zimbabwe
87. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States
88. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991
89. Estimating the mortality cost of AIDS: Do estimates of earnings differ?
90. Assessing the economic impact of AIDS in local communities. Current and projected costs for San Diego County
91. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium
92. The AIDS epidemic in Sweden: Estimates of costs, 1986, 1987 and 1990
93. Economic impact of the AIDS epidemic in the European Community: Towards multinational scenarios on hospital care and costs
94. Economic consequences of HIV/AIDS in India
95. The impact of AIDS in a rural Ugandan community
96. Costs to business for an HIV-infected worker
97. Potential and actual workdays lost among patients with HIV
98. Decreased morbidity and use in hospital services in English HIV infected individuals with increased uptake of anti-retroviral therapy 1996-1997
99. The friction cost method for measuring indirect costs of disease
100. The medical care cost of human immunodeficiency virus-infected children in Harlem
101. Pediatric acquired immuno-deficiency syndrome hospitilizations in New Jersey
102. Pediatric AIDS at Mount Sinai Medical Center 1988-89: A study of costs and social severity
103. Pediatric human immunodeficiency virus infection: Recent evidence on the utilization and costs of health services
104. Lifetime cost of care for children with human immunodeficiency virus infection
105. Health care and its costs for children with perinatally acquired HIV infection
106. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre
107. Paediatric treatment costs and the HIV epidemic
108. Health economics in HIV disease: A review of the European literature
109. Decline in deaths from AIDS due to new antiretrovirals
110. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
111. Health Africa: UN Security Council, breaking tradition, takes up AIDS
112. Assessing HIV service provision: Why costs are also important
113. Counting the cost of HIV service provision in England: Where do we go from here?